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Background 
 
Opioids are widely used for providing analgesia for acute and chronic pain, including cancer 
pain. Global use of opioids has risen dramatically since the early 2000s 1, with the highest levels 
of opioid consumption accounted for by use in high income countries such as the United States, 
Canada and Australia2. In many countries there have been well-documented increases in 
morbidity and mortality associated with the increased use of opioids3-9, which has led to a need 
to gain a deeper understanding of the manner in which opioids are used and changing patterns 
of use. Further, with increasing availability of different opioids and different formulations, 
understanding opioid use at the population level has become increasingly complex. 
This growing research area examining pharmaceutical opioid use has led to a need to develop 
clear ways to represent and compare opioid use. For drug utilisation in particular, there is a 
need to present usage data consistently, taking into account dosing requirements. One method 
of representing opioid use at the population level is through the application of Defined Daily 
Doses (DDD). However, representing opioid use as DDDs may not optimally represent clinical 
dosing of opioids10, partly because opioids require highly individualised dosing and need to be 
titrated to pain response, rather than having standard therapeutic dose ranges. 
An alternate way to represent opioid use and address the limitations of using DDDs, is through 
the application of oral morphine equivalents (OMEs). Oral morphine equivalents are based on 
the idea that different doses of different opioids may give a similar analgesic effect. Where the 
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doses of two different opioids are considered to give a comparable analgesic effect, they are 
deemed to be equianalgesic doses.    
Equianalgesic doses of opioids were initially developed using data from studies of acute opioid 
dosing in opioids naïve participants10, 11, limiting their relevance to use of opioids for chronic 
pain, the indication representing the majority of opioid consumption today. Further, there are 
now a large number of dose conversion tables available and conversion factors vary widely. 
Combined with multiple patient-related factors to consider when converting doses, there is the 
potential to calculate very different results for the same patient’s dose 11. This has led to 
different groups and hospitals developing their own guidelines to take into account clinical 
experience, and new research reporting conversions with chronic opioid use12.  
From a research perspective, it is important to have a comprehensive resource which will 
enable comparisons between opioid use in different geographic locations and between 
populations over different time points. Currently, available tables do not cover the full range of 
opioids used in Australia, and international references appear to report only a limited number 
of opioids used in Australia. For this reason, we sought to develop a comprehensive dose 
conversion table, and report a transparent methodology to support the conversion used. As 
most of the published literature and guidelines report doses in OMEs, we have compiled a 
reference that represents a broad range of opioids with simple conversion factors to facilitate 
representing doses of a wide range of opioids in OMEs.  
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Methods 
A table for converting opioids into OMEs was initially created using leading clinical references in 
Australia: the Therapeutic Guidelines13, the Australian Medicines Handbook14 and a consensus 
document developed by the Faculty of Pain Medicine of the Australian and New Zealand 
College of Anaesthetists (FPMANZCA) 2014. Conversions were mostly consistent across 
references. Where conversion factors were available from multiple sources, the most 
commonly occurring value was used to establish the final conversion factor.  In the case of 
methadone, which is rarely reported in clinical conversion tables, conversion factors were 
adapted from Walker et al. 15.  To ensure that the conversion factors reported were consistent 
with international recommendations, we then examined conversion rates published in national 
prescribing guidelines or by organisations in Canada, the United Kingdom, the United States 
and Europe, representing some of the highest opioid consuming regions in the world. Finally, 
we examined a systematic literature review of chronic opioid dosing studies12. While wide 
ranges were reported in this review, reflecting normal clinical variation, the conversion factors 
we have chosen to use are within the reported ranges. 
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Table 1: Conversion factors from Australian sources  
  ANZCA 
guidelines
16
 
eTherapeutic 
Guidelines
17
  
Australian Medicines 
Handbook
18
 
Other sources Recommended OME 
Conversion factor 
ORAL PREPARATIONS      
Swallowed       
morphine mg/day 1 1 1  1 
oxycodone mg/day 1.5 1.5 1.5 - 2  1.5 
hydromorphone mg/day  5 5-6.7 4-5  5 
codeine mg/day 0.13 0.13 0.15  0.13 
dextropropoxyphene mg/day 0.1 not listed not listed  0.1 
tramadol mg/day 0.2 0.2 0.2   0.2 
tapentadol mg/day 0.4 not listed not listed 0.36
19
  0.4 
methadone mg/day not listed not listed not listed 4.7
20
 4.7  
Buccal/Sublingual      
buprenorphine  mg/day 40 37.5 37.5   37.5 
fentanyl   mcg/day 0.1 not listed not listed  0.1 
sufentanil  mcg/day 0.5 not listed not listed  0.5 
TRANSDERMALPREPARATIONS      
buprenorphine mcg/hr 2 2.5 not listed  2.5 
fentanyl mcg/hr 3 
2.5 - 5 (12mcg/hr)               
2.4 - 4  
(25-100mcg/hr) 
not listed 
 
3 
PARENTERAL PREPARATIONS      
morphine   (sc, iv) mg/day 3 3 3  3 
oxycodone  (sc, iv) mg/day 3 3 not listed  3 
hydromorphone (sc,iv) mg/day 15 15-20 15-20  15 
codeine  (sc, iv) mg/day 0.25 not listed not listed  0.25 
pethidine (iv, im) mg/day 0.4 not listed 0.3 - 0.4  0.4 
fentanyl  (iv,im,sc) mcg/day 0.2 0.15 - 0.2  0.2 - 0.3  0.2 
sufentanil  (iv, sc) mcg/day 2 not listed not listed  2 
methadone (iv) mg/day not listed not listed not listed  13.5
20
 13.5 
buprenorphine (im, iv) mg/day not listed 75 75  75 
RECTAL PREPARATIONS      
oxycodone  mg/day 1.5 not listed not listed  1.5 
iv = intravenous; sc=  subcutaneous; im = intramuscular. 
 Note: for eTherapeutic Guidelines, Tables 1.14, 1.8, and 10.9 were used. 
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Table 2. Comparison of recommended OME conversion factor with those recommended by key international sources 
  Australia United Kingdom United States Canada Europe 
  Recommended 
research OME 
Conversion factor 
British National 
Formulary 66
21
 
UKMi
22
 Lexicomp Drug 
Information 
Handbook
23
 
National Opioid 
Use Guideline 
Group
24
 
European 
Association for 
Palliative Care
25
 
ORAL PREPARATIONS       
Swallowed        
morphine mg/day 1   1  1 
oxycodone mg/day 1.5 1.5 1.3-2 1-2 1.5 1.5 
hydromorphone mg/day  5 5 3.5-10 4 5  
codeine mg/day 0.13 0.1 0.08-0.15  0.15  
dextropropoxyphene mg/day 0.1      
tramadol mg/day 0.2  0.1-0.25    
tapentadol mg/day 0.4  0.3-0.4    
methadone mg/day 4.7      
Buccal/Sublingual         
buprenorphine  mg/day 37.5  30-80*    
fentanyl  mcg/day 0.1      
sufentanil  mcg/day 0.5      
TRANSDERMAL PREPARATIONS       
buprenorphine mcg/hr 2.5     1.7 
fentanyl mcg/hr 3     2.4 
PARENTERAL PREPARATIONS       
morphine   (sc, iv) mg/day 3 2  3   
oxycodone  (sc, iv) mg/day 3      
hydromorphone (sc,iv) mg/day 15   20   
codeine  (sc, iv) mg/day 0.25      
pethidine (iv, im) mg/day 0.4      
fentanyl  (iv,im,sc) mcg/day 0.2   0.3   
sufentanil  (iv, sc) mcg/day 2      
methadone (iv) mg/day 13.5      
buprenorphine (im, iv) mg/day 75   75   
RECTAL PREPARATIONS       
oxycodone  mg/day 1.5      
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Considerations when using OMEs for research purposes 
 
There are some considerations and caveats when using these conversion factors: 
 Firstly, these conversion factors are based on clinical guidelines for chronic opioid dosing, 
including use in both chronic pain and palliative care, which represents the majority of all 
opioid prescribing. Consequently, conversion factors may differ for acute dosing.  
 Many guidelines do not publish conversion rates for methadone, or publish conservative 
rates due to concerns about incomplete cross tolerance or opioid toxicity with long-acting 
opioids. As such we have based on our conversion based on published transfers in the 
direction of methadone to morphine. 
 Although ranges are typically reported for dose conversion for some opioids, we have 
included a single conversion factor, which generally represents a midpoint or modal value of 
available conversion factors to enable calculation of specific doses. In reality, large ranges 
exist for dose conversion, representing normal inter-patient variation.  
 Where combination analgesics are used, we have only considered the opioid ingredient in the 
conversion factor as our goal is to represent only opioid use/consumption rather than 
equipotent analgesic effect of both ingredients in a combination product.  
 Our conversion factors are intended to calculate conversions from other opioids to OMEs. 
Different conversions may be suggested if converting to opioids other than morphine, as 
conversion rates vary based on the direction of the conversion. 
 Finally, concerns about opioid tolerance and potential toxicity, inter-individual variation, 
concomitant medication use and interactions, renal and hepatic impairment, are just a few of 
 ©NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2014 7 
the many reasons why in clinical practice changing between opioids must be carefully titrated 
on an individual basis, with conversion tables at best offering a guide as to potential 
requirements, as opposed to a suggested dose.   
For the reasons listed above, these OMEs should not be taken as being suggested for use for 
clinical purposes. The reader is directed to many of the references consulted in compiling this 
table for clinical recommendations on dose conversions. 
Conclusions 
These OMEs provided are a comprehensive document reflecting opioids currently used in 
Australia. These conversion factors are currently being used in studies estimating opioid use at a 
population level, and examining changes in opioid use over time.  
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